Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.
暂无分享,去创建一个
M. Humbert | V. Steen | V. McLaughlin | P. Nash | G. Coghlan | P. Nash
[1] A. Gabrielli,et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases , 2007, Annals of the rheumatic diseases.
[2] R. Barst,et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. , 2007, The Journal of rheumatology.
[3] M. Humbert,et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension , 2007, European Respiratory Journal.
[4] E. Kerem,et al. Pregnancy and chronic progressive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[5] P. Hassoun,et al. N-terminal brain natriuretic peptide in scleroderma-associated pulmonary arterial hypertension. , 2006, European heart journal.
[6] K. Lewis. Pulmonary Arterial Hypertension in France: Results from a National Registry , 2007 .
[7] D. Badesch,et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. , 2007, Chest.
[8] R. Barst,et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. , 2006, American journal of respiratory and critical care medicine.
[9] C. Ricachinevsky,et al. Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.
[10] M. Humbert,et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions , 2006, Annals of the rheumatic diseases.
[11] R. Barst,et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. , 2006, Journal of the American College of Cardiology.
[12] J. Loscalzo,et al. Pulmonary arterial hypertension. , 2004, Annals of medicine.
[13] M. Pillinger,et al. Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension , 2006 .
[14] M. Humbert,et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. , 2005, Arthritis and rheumatism.
[15] C. Denton,et al. Targeted therapy comes of age in scleroderma. , 2005, Trends in immunology.
[16] D. Badesch,et al. Ambrisentan therapy for pulmonary arterial hypertension. , 2005, Journal of the American College of Cardiology.
[17] J. Lima,et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). , 2005, Arthritis and rheumatism.
[18] E. Bossone,et al. Pulmonary arterial hypertension: the key role of echocardiography. , 2005, Chest.
[19] S. Rich,et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. , 2004, Chest.
[20] D. Mccrory,et al. Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines , 2004 .
[21] D. Mccrory,et al. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[22] D. Mccrory,et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. , 2004, Chest.
[23] A. Fishman. Primary pulmonary arterial hypertension: a look back. , 2004, Journal of the American College of Cardiology.
[24] M. Humbert,et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[25] R. Budhiraja,et al. Endothelial Dysfunction in Pulmonary Hypertension , 2004, Circulation.
[26] A. Holmes,et al. Significance of plasma N-terminal pro-brain natriuretic peptide in patients with systemic sclerosis-related pulmonary arterial hypertension. , 2003, Respiratory medicine.
[27] D. Badesch,et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. , 2003, Chest.
[28] T. Medsger,et al. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. , 2003, Arthritis and rheumatism.
[29] S. Kimmel,et al. Hemodynamics and survival in patients with pulmonary arterial hypertension related to systemic sclerosis. , 2003, Chest.
[30] S. Rich,et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.
[31] Orris,et al. INHALED ILOPROST FOR SEVERE PULMONARY HYPERTENSION , 2002 .
[32] Avid,et al. BOSENTAN THERAPY FOR PULMONARY ARTERIAL HYPERTENSION , 2002 .
[33] R. Speich,et al. Clinical classification of pulmonary hypertension. , 2004, Journal of the American College of Cardiology.
[34] D. Badesch,et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.
[35] K. Kangawa,et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.
[36] Stuart Rich,et al. Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease , 2000, Annals of Internal Medicine.
[37] M. Fujita,et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.
[38] L. Rubin,et al. Primary pulmonary hypertension. , 1997, The New England journal of medicine.
[39] A. Wells,et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. , 1997, British journal of rheumatology.
[40] M Abu-Shakra,et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. , 1996, British journal of rheumatology.
[41] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[42] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .